STENTYS completes enrollment of APPOSITION III study for its Self-Apposing Stent to Treat Heart Attacks

PRINCETON, N.J., and PARIS, Sept. 21, 2011 — STENTYS S.A. (STNT.PA), a medical technology company that is commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.

“The study completion is a critical milestone that was delivered on time and demonstrates the growing adoption of the Self-Apposing technology as the solution for treating heart attack patients,” said Gonzague Issenmann, CEO and co-founder of STENTYS. “Given the outstanding clinical results to date and the fast pace of enrollment, we have decided to continue enrollment in order to keep accumulating clinical data.”

“Cardiologists in our cath lab continue to be excited to participate in the APPOSITION III study and to have the advantage of using the STENTYS Self-Apposing Stent to treat our AMI patients,” added study investigator Dr. Karel Koch, M.D., Amsterdam Medical Center, Amsterdam, the Netherlands.

Acute Myocardial Infarction (AMI) affects 100,000 people each year in France and an additional 900,000 people in the United States and represents an annual worldwide market of approximately $2 billion.

• Next press release

Revenues for the 3rd quarter of 2011 will be published on 9 November 2011, after market.

About STENTYS: Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, STENTYS received CE marking for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has marketing activities in several European countries.


This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

STENTYS
Stanislas Plot
CFO
Tel. : +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Investor Relations
Axelle Vuillermet / Pierre Laurent
Tel. : +33 (0)1 44 71 94 93
stentys@newcap.fr

STENTYS is listed on NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT